/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Ganglioneuroblastoma is an emerging landscape with 16 programs across 10 companies. 16 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
88%
Small molecule
14 of 16 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 16 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.
Analysis
4
clinical trials
Clinical Trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)